A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative ...
Higher levels of BDNF in the blood were linked to both more severe depressive symptoms (HADS-D score) and more severe asthma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results